UNAIDS, WHO & the global HIV response — the road to 2030 runs through a funding crisis.

Two United Nations-linked bodies sit at the center of the global HIV response, and most people living with HIV have never heard either name spoken in a clinic. The Joint United Nations Programme on HIV/AIDS (UNAIDS) coordinates political commitment, tracks the epidemiology, and publishes the numbers every country measures itself against. The World Health Organization (WHO) writes the clinical guidance — who should get pre-exposure prophylaxis (PrEP), which antiretroviral regimen is first-line, how testing should work — that ministries of health, PEPFAR, and the Global Fund translate into actual services.

Their central roles are guidance, coordination, monitoring and support to countries. Clinical services depend on national systems and implementing partners. UNAIDS’s 2026 reporting describes substantial financing pressures that threaten continuity and progress.2

Two bodies, one mission — and both are strained

UNAIDS was established by a 1994 UN Economic and Social Council resolution and began operations in January 1996. It coordinates a joint response spanning health, development and human rights, produces epidemic estimates and supports countries and communities. UN Member States adopt political commitments; UNAIDS does not unilaterally set binding national policy.1

WHO develops evidence-based recommendations and supports public-health implementation. Countries adapt its HIV guidance to their own circumstances. A WHO recommendation is influential, but it does not automatically become law or replace national guideline development.3

The organizations have complementary and overlapping roles: WHO supplies clinical and public-health guidance, while UNAIDS coordinates, monitors and advocates. WHO recommended lenacapavir for PrEP in July 2025, and UNAIDS’s 2026 reporting tracks subsequent progress and funding pressures. At AIDS 2026, the IAS rapporteur summary records Tedros’s call for financing, community support and action on criminalization.24

For someone living with HIV, these institutions help explain how research becomes guidance and how countries assess access. Actual care decisions still depend on national recommendations, available services and an individual clinical assessment.

The numbers, as of the latest data

UNAIDS’s 2026 estimates for the end of 2025 put the number of people living with HIV at 41.0 million (uncertainty range 35.3–47.5 million), including 39.7 million adults and 1.3 million children under 15. Women and girls accounted for 53%. These end-2025 figures come from the current fact sheet, not a report published in July 2025.2

In 2025, an estimated 1.2 million people newly acquired HIV — down 65% from the epidemic's 1994 peak of roughly 3.5 million, and down 42% since 2010.2 An estimated 570,000 people died of AIDS-related illness that year, a 73% decline from the 2004 peak.2 Still: someone died of HIV-related causes roughly every minute of 2025.2 Progress has been real and progress has also stalled — new acquisitions fell fastest among children over the past decade, but that decline has flattened in recent years, amid persistent prevention gaps and more recent program disruption.2

By the end of December 2025, 32.1 million people were accessing antiretroviral therapy, up from 7.6 million in 2010 — a scale-up that remains one of the most consequential public-health achievements of this century.2 That is 78% of everyone living with HIV. It leaves roughly 8.9 million people living with HIV without treatment, including about 5 million who did not know their status. The undiagnosed group is part of that treatment gap, not an additional group to add to it.2

Where the gaps concentrate

The global averages hide sharp disparities by age, sex, and population. Treatment coverage for children (0–14) sits at 55%, far below the 79% coverage among adults.2 Coverage is also uneven by sex: 84% of women living with HIV were on treatment in 2025, versus 74% of men.2 UNAIDS's key-populations analysis found gay men and other men who have sex with men face 18 times the risk of HIV acquisition compared with all adults aged 15–49 in the reported comparison; people who inject drugs face 34 times the risk; sex workers and transgender women each face roughly 17 times the risk; and people in prisons and other closed settings have twice the HIV prevalence of the general population.2 These population comparisons are not predictions for an individual. Exposure patterns and biological factors interact with criminalization, stigma and unequal service access. WHO’s guidance addresses these structural barriers without treating identity itself as a cause of HIV.

95-95-95 — what the targets mean, and who is hitting them

The 90-90-90 targets, adopted in 2014, asked that by 2020, 90% of people living with HIV know their status, 90% of those diagnosed be on treatment, and 90% of those on treatment be virally suppressed. The world did not reach them on schedule, and UN Member States adopted the 95–95–95 targets in June 2021 for achievement by 2025, an interim checkpoint on the way to ending AIDS as a public health threat by 2030.1

The distinction matters practically, not just numerically. Multiplying 95% by 95% by 95% yields roughly 86% of all people living with HIV virally suppressed — a population-level target public-health programs can actually plan against, distinct from "everyone" and distinct from "cure."

Against that yardstick, the 2025 global cascade is: 88% of people living with HIV know their status; of those, 89% are on treatment; of those, 95% are virally suppressed.2 Multiplied through, roughly 74% of all people living with HIV worldwide are virally suppressed — real progress from a decade ago, and still short of the 86% population target.2 The gap is concentrated in the first two 95s — status awareness and treatment linkage — not in the third: the overall result hides important differences, including a third-95 estimate of 85% among children aged 0–14.2

Botswana’s 2021 national survey provided early evidence that reaching 95–95–95 was feasible. UNAIDS’s 2026 report identifies 11 countries reaching the targets in 2025: Botswana, Cambodia, Denmark, Eswatini, Lesotho, Namibia, Rwanda, Saudi Arabia, Sweden, Zambia and Zimbabwe. National totals can still hide shortfalls among children or other groups; check the reporting year and population before comparing countries.67

At AIDS 2026, leaders called for renewed financing, community participation and access to scientific advances. — Summary of the IAS rapporteur account of the opening session, July 27, 2026.4

Reaching 95–95–95 is a treatment-cascade milestone. It is not itself a universal mathematical threshold for “epidemic control,” a promise that transmission will stop, or evidence that all populations have equitable access. Progress also depends on sustained treatment, prevention and addressing inequalities.1

WHO’s consolidated guidelines — guidance for national programs

WHO’s 2021 consolidated guideline brings together recommendations on prevention, testing, treatment, service delivery and monitoring. Later publications update particular topics. The December 2025 clinical-management recommendations address ART, vertical transmission and tuberculosis prevention and are intended for incorporation into a forthcoming revision. Readers should consult the relevant current update alongside the 2021 volume.3

TLD as the global default

Dolutegravir-based ART remains a preferred WHO treatment approach. TLD combines tenofovir disoproxil fumarate, lamivudine and dolutegravir and is widely used in national programs. Regimen choice still depends on clinical circumstances, other medicines, resistance, tolerability and availability; a preferred option is not suitable for every person.8

WHO guidance informs national programs, but it does not mean everyone receives the same pill. U.S. NIH guidelines recommend several initial regimens selected for the individual, including bictegravir- and dolutegravir-based options. U.S. drug access and coverage also differ from procurement arrangements in PEPFAR-supported countries.20

Key populations — why the language and the framework both matter

WHO's July 2022 guidance, formally titled Consolidated Guidelines on HIV, Viral Hepatitis and STI Prevention, Diagnosis, Treatment and Care for Key Populations, names five groups: gay men and other men who have sex with men, trans and gender-diverse people, sex workers, people who inject drugs, and people in prisons and other closed settings.9 The guidance is explicit that what elevates HIV risk for these groups is not identity or behavior in isolation — it is the compounding effect of criminalization, stigma, and structural exclusion that obstructs access to prevention, testing, and treatment.9

WHO’s key-populations framework identifies groups experiencing high HIV burden and barriers to services. It calls for community leadership, equitable care and action on structural barriers. A respectful clinical assessment can still ask about actual exposures and prevention needs; those questions should be relevant and free of moral judgment.9

The amfAR-led PEPFAR Pulse Study, with Johns Hopkins and other partners, surveyed 166 prime implementing partners in 46 countries. Respondents reported at least 1,714 site closures and widespread interruptions, especially to prevention and key-population services. It was not a KFF survey, and its self-reported, nonrepresentative sample cannot establish how every local organization fared compared with every international implementer.2210

PEPFAR and the Global Fund — the money behind the guidelines

Guidelines only matter if someone pays for the drugs, tests, and staff to deliver them. Two mechanisms have carried most of that weight for two decades. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), launched in 2003 under President George W. Bush, is credited with saving more than 26 million lives.10 The Global Fund to Fight AIDS, Tuberculosis and Malaria, created in 2002 as a multilateral financing partnership, pools contributions from governments, foundations, and the private sector and channels them to country-led programs across all three diseases.

PEPFAR's 2025–2026 crisis, in sequence

PEPFAR has been reauthorized by Congress four times, most recently in March 2024 for one year; that authorization expired on March 25, 2025.10 Because PEPFAR is a permanent part of U.S. law, expiration of the time-limited authorization did not by itself end the program — but a separate, more disruptive sequence of executive actions did enormous damage in parallel. On January 20, 2025, the incoming administration issued an executive order requiring a 90-day review of foreign aid; a subsequent stop-work order froze essentially all PEPFAR programming, including ongoing distribution of antiretroviral therapy.10 A limited waiver on February 1–6, 2025 allowed treatment, testing, and prevention of mother-to-child transmission to resume, but explicitly excluded PrEP for anyone other than pregnant and breastfeeding women — cutting off ongoing PrEP users and new prevention enrollment for everyone else, including gay men, sex workers, and other key populations.10

USAID had obligated about 60% of PEPFAR bilateral assistance in FY 2023; remaining global-health activities moved to the State Department during 2025. KFF’s analysis of available award lists found HIV activities in 379 of 770 global-health awards, with 71% of those HIV-related awards listed as terminated. Counts of awards are not percentages of dollars or proof that PEPFAR as a whole will cease in 2027. The program’s future depends on appropriations, implementation and country-specific arrangements.1010

KFF’s FY 2026 accounting totals roughly $6.0 billion across PEPFAR accounts: about $4.7 billion for bilateral HIV work, $1.25 billion for the Global Fund and $45 million for UNAIDS. Appropriations authorize spending; they do not establish how much has been obligated, disbursed or received by service providers.23104

The Global Fund's parallel squeeze

The Global Fund announced $12.64 billion in final Eighth Replenishment pledges on February 18, 2026. It approved $10.78 billion in country allocations and $260 million in catalytic investments for the period described in that announcement. A pledge, a congressional appropriation and an actual payment are different measures; they should not be combined into a claim about delivered services.124

The IAS opening-session rapporteur summary describes calls to center access, protect community services and sustain financing. Its account presents innovation and implementation as linked priorities.13

Lenacapavir — the science moved faster than access

If there is one place the 2026 story is not only bad news, it is prevention science. Lenacapavir is a long-acting HIV-1 capsid inhibitor, given through initiation dosing followed by subcutaneous injections every six months, that produced two of the most striking PrEP trial results ever published. In the PURPOSE-1 trial, presented in 2024, cisgender women receiving twice-yearly lenacapavir had zero new HIV infections among more than 2,100 participants.14 PURPOSE-2, in cisgender men, transgender men, transgender women, and gender-nonbinary people who have sex with partners assigned male at birth, found a 96% reduction in HIV incidence compared with estimated background incidence and an 89% reduction compared with daily oral TDF/FTC — only two infections among 2,180 participants receiving lenacapavir, versus nine among 1,087 people on daily oral tenofovir disoproxil fumarate/emtricitabine.14

The FDA approved injectable lenacapavir for PrEP in June 2025, and WHO followed in July 2025 with new guidelines recommending it as an additional prevention option — a strong recommendation, based on moderate-to-high certainty evidence — alongside a companion recommendation supporting rapid diagnostic tests for people starting or continuing any long-acting injectable PrEP.15 WHO's Dr. Meg Doherty, director of the department overseeing global HIV programs, called it practical for real-world use: "Dosing every six months with LEN could be particularly appealing for individuals who prefer fewer visits to the clinic or face difficulties with daily oral PrEP. It has the potential to enhance adherence and extend its reach to those in need of HIV prevention."15

Gilead, lenacapavir's manufacturer, signed royalty-free voluntary licensing agreements in October 2024 with six generic manufacturers to produce and sell low-cost versions across 120 primarily low- and lower-middle-income countries, and committed to supplying its own product at no profit until generic supply catches up with demand.16 The October 2024 agreements preceded the June 2025 PrEP approval and were subject to regulatory approvals; licensing alone does not guarantee immediate supply or coverage in every country.

Licensing must be followed by regulatory approvals, manufacturing, procurement and service delivery. In September 2025, PEPFAR and the Global Fund announced a goal of reaching up to 2 million people with long-acting PrEP by 2028. That announced goal should be tracked against actual delivery rather than treated as people already reached.1310

U=U, globally — a message that travels further than a viral-load test does

U=U applies to sexual transmission: people who achieve and maintain viral suppression below 200 copies/mL do not transmit HIV through sex. Prevention Access Campaign helped communicate this evidence beginning in 2016. The original campaign statement and current CDC guidance are linked in reference 17. This does not mean HIV has been cured or that the zero-risk statement applies to breastfeeding or shared injection equipment.17

Access to viral-load testing helps people confirm and maintain suppression. Taking ART does not by itself establish a current viral-load result. UNAIDS’s global third-95 monitoring measure commonly uses a threshold below 1,000 copies/mL, which differs from the below-200 threshold used for U=U sexual-transmission counseling. WHO distinguishes undetectable viral load from a detectable but suppressed result; these categories should not be silently substituted for one another.242

Women and girls — a gendered epidemic, and where DREAMS fits

HIV has never distributed evenly by sex, and UNAIDS's 2025 data confirms the pattern persists: women and girls are 53% of everyone living with HIV worldwide and accounted for 44% of new acquisitions in 2025.2 The concentration is sharpest among adolescent girls and young women in Eastern and Southern Africa, where UNAIDS and PEPFAR have long documented dramatically higher incidence than among their male peers of the same age — driven by age-disparate relationships, gender-based violence, economic dependency, and school dropout, alongside biological and exposure-related factors that also affect acquisition risk21.

PEPFAR's DREAMS partnership — Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe — launched in 2014 with private-sector partners including the Bill & Melinda Gates Foundation, Gilead, Johnson & Johnson, and ViiV Healthcare, specifically to address those structural drivers rather than treat HIV risk in adolescent girls as an individual behavior problem.18 The model layers interventions — HIV prevention services, gender-based-violence response, secondary-school support, economic strengthening — to address several interacting barriers at the same time. The program’s 2019 fact sheet reported reductions of at least 25% in new diagnoses among adolescent girls and young women across nearly all participating geographic regions. This is a dated program report; the statistic alone does not isolate DREAMS’s causal effect.18

DREAMS is also one of the programs KFF specifically found scaled back amid the 2025 funding disruption, with declining support recorded through FY 2025 Q4 and continuing negative effects on programs for adolescent girls and young women reported as of December 2025.10 A program built on the recognition that gender-based violence and HIV cannot be addressed separately is now itself a casualty of the same funding contraction affecting other prevention services.

The advocacy space — what pressure at the UN and WHO level actually does

Neither UNAIDS's targets nor WHO's guidelines write themselves, and neither gets adopted by governments automatically. A network of advocacy and community organizations does the work of translating evidence into political pressure and holding both bodies, and the donor governments behind them, accountable. AVAC has spent decades building the evidence-to-advocacy pipeline for HIV prevention research specifically, including sustained work with key-population communities and organizations to make sure new prevention tools like lenacapavir reach the populations the trials were designed to serve.19 The International AIDS Society (IAS) convenes the biennial International AIDS Conference — AIDS 2026 drew HIV researchers, clinicians, and advocates to Rio de Janeiro, Brazil, in July 2026 — and its president has become one of the most visible public voices naming the funding crisis for what it is.13

Community and women-led organizations occupy a different, equally necessary lane: groups built and led by people living with HIV, including networks organized specifically around women living with HIV, push UNAIDS and WHO to keep lived experience inside guideline development rather than treating affected communities purely as guidance recipients. That is consistent with both organizations' own stated commitments to "nothing about us without us" — a principle easier to state than to operationalize when guideline committees, donor boards, and country programs all still skew toward technical experts over people actually living with HIV.

Advocacy organizations can make evidence and access barriers visible, participate in policy debate, and hold institutions accountable. The AIDS 2026 program and rapporteur record show community participation in those discussions. Specific court outcomes or wording decisions should not be credited to unnamed advocacy efforts without direct evidence.1013

What you can do

None of this is abstract for a person living with HIV whose local clinic depends, even indirectly, on PEPFAR or Global Fund financing — and even for people in well-resourced health systems, the global response's stability affects drug pricing, research investment, and the political climate around HIV everywhere.

AIDS 2026, the 26th International AIDS Conference, was held in Rio de Janeiro, Brazil, in July 2026, under the theme "Rethink. Rebuild. Rise." — a framing IAS chose deliberately for a moment defined as much by funding collapse as by scientific breakthrough.13 The next major global checkpoints are implementation of the Global Fund’s Eighth Replenishment commitments and UNAIDS’s next published estimates — both worth watching if you want a dated view on whether 2026's crisis becomes 2027's recovery or 2027's collapse.

Florida In Focus — the domestic parallel, and where the federal thread runs through it

Florida has no direct role in PEPFAR or the Global Fund — those are foreign-assistance mechanisms, and Florida's own HIV epidemic is served through a different federal architecture, chiefly the Ryan White HIV/AIDS Program and state AIDS Drug Assistance Programs. But the connection is not merely rhetorical. The same State Department Bureau of Global Health Security and Diplomacy now responsible for PEPFAR's remaining operations sits inside the same broader shift in how the federal government thinks about global health obligations — and the domestic equivalent of "will Congress keep funding this line item at prior-year levels" is a live question for Ryan White appropriations too, not just for PEPFAR.10

Florida clinicians can offer FDA-approved HIV prevention options, including lenacapavir for eligible HIV-negative adults and adolescents weighing at least 35 kg. Its U.S. prescribing information requires initiation dosing and HIV testing before initiation and each subsequent injection. Coverage and access depend on U.S. programs and insurers; the 120-country voluntary-license arrangement does not govern routine access in Florida.2514